Palmetto GBA, a Medicare administrative contractor that assesses molecular diagnostic technologies, has issued a draft local coverage determination for the Oncotype DXGenomic Prostate Score issued a draft LCD that recommends Medicare coverage for use of the test in qualified patients with favorable intermediate-risk prostate cancer.
At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.
